The group hopes to improve civic education in a state that ranks among the bottom nationally when it comes to voter registration and turnout.
Lilly to install $10M worth of solar panels at two Indianapolis campuses
The solar structures are designed to help generate power for the company and reduce its carbon footprint.Read More
Eli Lilly sues businesses selling knockoff versions of Mounjaro
Lilly is suing medical spas, wellness centers and compounding pharmacies in various U.S. states that sell unapproved versions of its blockbuster diabetes drug, which is frequently used off-label for weight loss.Read More
Lilly stock skyrockets, raising profile of city’s life sciences sector
The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.Read More
Lilly reports surging profit, raises full-year guidance
The Indianapolis-based pharmaceutical company’s first-quarter performance was driven by strong sales of leading drugs for diabetes, cancer and other diseases.Read More
The Biden administration is targeting diabetes treatment Jardiance and nine other medications for Medicare’s first-ever drug price negotiations as it seeks to lower medical costs for Americans.
Much of the excitement is due to strong results from Mounjaro, which hit the market in June 2022 as a treatment for Type 2 diabetes and rang up $979.7 million in the quarter.
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after rival Leqembi. Both drugs pose a serious safety concern—brain swelling and bleeding.
More than 110,000 Hoosiers suffer from Alzheimer’s disease, which robs people of their memories and abilities to do daily tasks, and is the nation’s sixth-leading cause of death.
With the acquisition of Versanis Bio, Lilly is adding another promising treatment to its weight-loss drug pipeline.
The EMA said it would consider whether its review should be extended to other drugs in the same class, known as GLP-1 receptor agonists. Indianapolis-based Eli Lilly and Co.’s Mounjaro is among them.
In this week’s edition of the IBJ Podcast, reporter John Russell discusses Medicare’s new power to negotiate drug prices and its effects on patients, drug makers and the rest the health care industry. Eli Lilly and Co. would like to see some changes.
The Indianapolis-based drugmaker said it will acquire Sigilon Therapeutics Inc., a six-year-old startup that is developing a technology to help type 1 diabetes patients restore insulin production over sustained periods.
Medical experts predict the pills will be popular, especially among people who want to lose weight but are fearful of needles.
Indianapolis-based Elevance Health, which operates Anthem plans, said that in most cases, it won’t cover Ozempic unless a patient is diagnosed with diabetes and has tried another medication to manage it, but physicians can still prescribe it.
Groups such as the Alzheimer’s Association have pushed Medicare to cover the new Alzheimer’s drugs—including those cleared on an expedited basis—saying that the FDA should be the final arbiter of safety and efficacy of drugs.
Under the agreement, Lilly has agreed to continue its cap on out-of-pocket costs for its users at $35 a month for four years.
A judge ruled that Indianapolis-based Lilly was liable for higher payments due to its behavior in making false statements to the Centers for Medicare and Medicaid Services about the prices it charged distributors for its drugs.
If approved, Donanemab has annual multi-billion-dollar sales potential. Lilly shares rose 6% in early-afternoon trading.
Coming off record fundraising year, Indiana’s life science sector looks for even more capital in 2023
Inventors and entrepreneurs who don’t have a track record face the biggest challenges, a panel of experts said Friday morning at IBJ’s Life Sciences Power Breakfast.
If approved for weight loss, Eli Lilly’s tirzepatide could become the most effective drug to date in an arsenal of medications that are transforming the treatment of obesity, which affects more than 4 in 10 American adults and is linked to dozens of diseases.
The Indianapolis-based drugmaker said it would complete submission of tirzepatide to the U.S. Food and Drug Administration in coming weeks for treatment of obesity and expects regulatory action as early as late 2023.